Rangwala Reshma 4

What Happened Reshma Rangwala, EVP and Chief Medical Officer of Karyopharm Therapeutics (KPTI), sold 449 shares on April 21, 2026. The shares were disposed at $8.94 per share for a total proceeds of approximately $4,014. The filing shows this was a broker-assisted sale to satisfy tax withholding on vested restricted stock units (RSUs), not a discretionary trade by the reporting person.

Key Details

• Transaction date: 2026-04-21; Filing date: 2026-04-22 (timely).
• Transaction type/code: Sale (S) — open market / broker-assisted sale.
• Shares sold: 449 at $8.94 per share; total proceeds ≈ $4,014.
• Footnote: Sale effected under a durable automatic sale instruction plan (adopted April 4, 2022) to cover withholding tax on RSU vesting; not a discretionary trade.
• Shares owned after the transaction: Not specified in the information provided.

Context This was a tax-withholding sale tied to RSU vesting rather than a voluntary market-timed sale. Such broker-assisted or withholding sales are common and primarily administrative; they do not necessarily reflect the insider’s view on the company’s prospects.